Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2026-02-28 @ 9:33 AM
Study NCT ID:
NCT07232602
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-11-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-10-18
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-10-18
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-14
First Submit QC Date:
None
Study First Post Date:
2025-11-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-19
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED